Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (ALLO) is a clinical-stage biotechnology leader developing off-the-shelf CAR T cell therapies for cancer and autoimmune diseases. This news hub provides investors and industry professionals with timely updates on clinical advancements, regulatory milestones, and strategic partnerships shaping the future of allogeneic cell treatments.
Access authoritative updates on ALLO's innovative pipeline, including progress with Dagger® technology and CRISPR-engineered therapies. Our curated news collection offers:
- Press releases detailing trial results and FDA interactions
- Financial reports and earnings call summaries
- Analysis of collaborations with academic and industry partners
- Updates on manufacturing scalability and therapeutic applications
Bookmark this page for centralized access to verified information on Allogene's progress in creating accessible, next-generation cell therapies. Check regularly for developments in hematologic malignancies, solid tumor treatments, and autoimmune disease research.
Allogene Therapeutics (Nasdaq: ALLO) has activated three community cancer centers for its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma (LBCL). The trial aims to improve 1L cure rates for patients with minimal residual disease (MRD). The centers include Rocky Mountain Cancer Centers, Astera Cancer Care, and Norton Cancer Institute. Detection of MRD will use the Foresight CLARITY IUO MRD test, powered by PhasED-Seq. Enrollment is expected to complete by 1H 2026, with a potential BLA submission in 2027. The trial could expand access to CAR T therapies in community settings, where 80% of patients are treated.
Community-based practices are first to enroll in ALPHA3, signaling a move to broader CAR T adoption. This trial addresses two key questions: can circulating tumor DNA predict relapse, and does cema-cel improve cure rates compared to conventional methods? With over 19 locations in Colorado, RMCC provides comprehensive cancer care. ACC, part of OneOncology, serves over 22,000 patients annually through 13 locations. Norton Cancer Institute, with 21 locations, treats over 4,000 new patients yearly.
Allogene Therapeutics has initiated the pivotal Phase 2 ALPHA3 trial to evaluate cemacabtagene ansegedleucel (cema-cel) as part of the first-line treatment for large B-cell lymphoma (LBCL) patients likely to relapse. The trial aims to improve cure rates by using Foresight Diagnostics' CLARITY™ test to identify patients with minimal residual disease (MRD) who need further treatment. Enrollment is expected to be completed in the first half of 2026, with a Biologics License Application (BLA) submission anticipated in 2027. The trial will enroll approximately 240 patients and will assess the efficacy of cema-cel in improving event-free survival (EFS) compared to the current standard of care.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company specializing in allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases, will participate in the TD Cowen 5th Annual Oncology Innovation Summit.
The event is scheduled for May 28, 2024, at 9:30 am PT/12:30 pm ET. A webcast will be available on the company's website under the Investors section. Replays of the webcast will be accessible for approximately 30 days.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech firm, announced a $110 million common stock offering, pricing 37,931,035 shares at $2.90 each. The offering, backed by mutual funds, institutional investors, and the company's board and executives, is expected to close by May 16, 2024. Managed by Goldman Sachs, the offering is under a shelf registration statement filed in March and declared effective by the SEC in April 2024. The proceeds will be used for continued development of their AlloCAR T™ products for cancer and autoimmune diseases.
Allogene Therapeutics reported first-quarter 2024 financial results and significant business updates. Key highlights include the expansion of CD19 oncology rights to all EU member states and the UK, increasing the potential market for Cema-Cel from $6 billion in the US to $9.5 billion combined. The pivotal Phase 2 ALPHA3 trial for LBCL is set to begin mid-2024, with initial data from the Phase 1 CLL trial expected by year-end 2024. The company also announced plans for ALLO-329, targeting autoimmune diseases, with IND submission by Q1 2025 and proof-of-concept data by YE 2025. Additionally, a $15 million grant from CIRM will support the Phase 1 TRAVERSE trial in RCC, with data updates expected by YE 2024. Financially, Allogene reported a net loss of $65 million for the quarter, with $397.3 million in cash and a projected cash runway into 2026.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will report first quarter 2024 financial results and provide a business update on May 13, 2024. The company specializes in allogeneic CAR T products for cancer and autoimmune disease. A live audio webcast and conference call will follow the announcement.
FAQ
What is the current stock price of Allogene Therapeutics (ALLO)?
What is the market cap of Allogene Therapeutics (ALLO)?
